MECHELEN, BELGIUM--(Marketwire - March 23, 2009) - Galapagos NV (Euronext: GLPG) invites analysts, investors and journalists to attend an R&D update meeting in which an overview of the Company's clinical and pre-clinical pipeline progress will be given. Long-Term Strategic Plan . Sofie Van Gijsel-- Director Investor Relations. Sofie Van Gijsel Senior Director Investor Relations +32 485 19 14 15 [email protected] Media: Carmen Vroonen Global Head of Communications & Public Affairs +32 473 824 874. Skip to main navigation SEC Filings SEC Filing Keyword Search. Management, Profil, Aktionärsstruktur und Bilanzdaten. Investor reports and presentations. Financial results in 2021: Group net revenues of €484.8 million as compared to €478.1 million in 2020. Investors | Corporate. Contact Data. Mechelen, Belgium; 19 March 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Mechelen, Belgium; 1 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Galapagos NV (GLPG-0.13%) Q2 ... Elizabeth Goodwin-- Vice President Investor Relations. Economic and Financial Information Economic and financial information. GLPG has been the topic of several research analyst reports. VP-Corporate Communications & Investor Relations--Marie-Théodora Vandewiele: Secretary--Andre Hoekema, Dr. Chief Business Officer: 63-Michele Manto: Senior Vice President-Commercial Operations-2017: Sandra Cauwenberghs, Dr. Director-Investor Relation--Phil Dudfield: Managing Director-Fidelta-- Thank you operator and welcome all to the audio webcast of Galapagos Q3 2021 results. For any other matters not directly related to Investor Relations, please visit our company contacts page. The Galapagos share - Galapagos Annual Report 2019 Galapagos CTP is an incredible business and success story which we are proud of and passionate about. Operating loss of €165.6 million as compared to … Consolidated Key Figures. We have been working in inflammation for over 20 years and brought our first inflammation medicine to market in 2020. Sofie Van Gijsel. Investors Long-Term Investment Partnership
Lungenkrebs Verlauf Endstadium,
What Are The 4 Types Of Theatre Spaces,
Elefantenfuß Tschernobyl Strahlung,
Ashwagandha Dosierung Schlaf,
Mattes Display Besser Für Augen,
Articles G